OMERS ADMINISTRATION Corp Purchases 23,700 Shares of Halozyme Therapeutics, Inc. $HALO

OMERS ADMINISTRATION Corp raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 47.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 73,789 shares of the biopharmaceutical company’s stock after purchasing an additional 23,700 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Halozyme Therapeutics were worth $4,769,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Halozyme Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after acquiring an additional 25,731 shares during the period. Norges Bank bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $128,201,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $124,031,000. Finally, Federated Hermes Inc. grew its stake in shares of Halozyme Therapeutics by 8.5% in the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after acquiring an additional 123,917 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $55,088,215. This represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,102 shares of company stock valued at $5,205,798 in the last ninety days. 2.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have weighed in on HALO. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. HC Wainwright reissued a “buy” rating and issued a $95.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, UBS Group reiterated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Performance

HALO opened at $81.48 on Tuesday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a 52-week low of $57.67 and a 52-week high of $83.50. The firm has a market cap of $9.66 billion, a P/E ratio of 29.31, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84. The business’s fifty day moving average is $73.36 and its 200-day moving average is $70.63.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the previous year, the firm earned $1.11 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.